-transparent.png){kind=logo}
600 mg of bezafibrate daily were administered to 13 well controlled diabetics with hyperlipidaemia for 12 weeks. Placebo was given before and after the treatment period. Compared with pretreatment placebo, bezafibrate reduced triglycerides (between 37 and 47%) and cholesterol (between 12 and 19%) significantly. Blood glucose levels during treatment were significantly lower at 8 and 12 weeks compared with post-treatment placebo values. Urinary glucose excretion did not change. Hypoglycaemia was not observed. No change in antidiabetic medication was necessary. Bezafibrate was well tolerated. It lowered blood lipids effectively in diabetics with hyperlipidaemia. No additional precautions have to be taken to control carbohydrate metabolism during bezafibrate treatment.
P Wahl, and
C Hasslacher, and
P D Lang, and
J Vollmar
November 1994,
The Indian journal of medical research,
P Wahl, and
C Hasslacher, and
P D Lang, and
J Vollmar
March 1976,
Rinsho byori. The Japanese journal of clinical pathology,
P Wahl, and
C Hasslacher, and
P D Lang, and
J Vollmar
May 1982,
Therapie der Gegenwart,
P Wahl, and
C Hasslacher, and
P D Lang, and
J Vollmar
June 1999,
Diabetic medicine : a journal of the British Diabetic Association,
P Wahl, and
C Hasslacher, and
P D Lang, and
J Vollmar
July 1974,
Deutsche medizinische Wochenschrift (1946),
P Wahl, and
C Hasslacher, and
P D Lang, and
J Vollmar
December 2008,
Current opinion in lipidology,
P Wahl, and
C Hasslacher, and
P D Lang, and
J Vollmar
January 2001,
Indian heart journal,
P Wahl, and
C Hasslacher, and
P D Lang, and
J Vollmar
March 2003,
Orvosi hetilap,
P Wahl, and
C Hasslacher, and
P D Lang, and
J Vollmar
January 1973,
Drugs,
P Wahl, and
C Hasslacher, and
P D Lang, and
J Vollmar
May 2001,
The Netherlands journal of medicine,
